Add BrightSurf on Google Email

New precision therapy for bile duct cancer extends patients’ lives

A new personalized treatment for bile duct cancer has shown remarkable results, with patients surviving for up to two years when treated with the drug futibatinib. The Phase II clinical trial found that the drug was more effective at reducing tumor size and producing modest side effects compared to chemotherapy.

SourceUniversity College London·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateJan 18, 2023

Pusan National University researchers identify therapeutic targets to overcome radioresistance of brain cancer cells

A team of researchers from Korea and USA identified the importance of lipid homeostasis in overcoming brain cancer radioresistance. They found that regulating diacylglycerol kinase B and diacylglycerol acyltransferase 1 could potentially sensitize brain cancer cells to radiotherapy, offering a new treatment strategy.

SourcePusan National University·JournalCell Reports Medicine·TypeExperimental study·DateJan 18, 2023

X-ray light reveals how virus responsible for COVID-19 covers its tracks, eluding the immune system

A new study uses serial femtosecond X-ray crystallography to reveal the structure of NendoU protein at room temperature. The resulting high-resolution image shows that the protein's flexibility plays a crucial role in its functional mechanism, which is essential for designing antiviral drugs against SARS-CoV-2.

SourceArizona State University·JournalStructure·TypeExperimental study·DateJan 10, 2023

New support for a serotonin deficit in depression

Researchers found reduced serotonin release capacity in individuals with depression, suggesting a blunted serotonin system. The study used novel imaging techniques to measure serotonin levels in the brain, providing crucial insights into the pathology of depression.

SourceElsevier·JournalBiological Psychiatry·TypeExperimental study·DateDec 15, 2022

Copper a clue in the fight against cancer

Researchers discovered that the Memo1 protein binds copper ions, blocking toxic redox reactions that damage or kill cancer cells. The protein's interaction with copper also protects against metastasis formation in breast cancer cells. This finding opens up potential new treatments for cancer.

SourceChalmers University of Technology·JournalProceedings of the National Academy of Sciences·TypeExperimental study·DateNov 10, 2022

Cleveland Clinic study identifies blood pressure drug as potential treatment for Black patients with Alzheimer’s disease

A new study published in Alzheimer's & Dementia found that telmisartan, a blood pressure medication, is associated with lower risk of Alzheimer's specifically in Black patients over 60. The study analyzed data from over 5 million patients and suggests that future clinical trials should prioritize minority populations to find or reinfor...

SourceCleveland Clinic·JournalAlzheimer s & Dementia·DateNov 4, 2022

NIH grant funds HIV research

Researchers at the University of Cincinnati are awarded a $3.5 million NIH grant to examine how alcohol use alone or in combination with fentanyl affects HIV medications, including PrEP medication. The study aims to determine metabolite signatures and pharmacological biomarkers of PrEP in HIV-negative populations.

Cancer drug could potentially be used against malaria

Researchers found that sapanisertib can kill the malaria parasite at several stages during its life cycle, including in the liver and red blood cells. The study's findings offer new hope against a disease that kills over half a million people annually.

SourcePenn State·JournalScience Translational Medicine·TypeExperimental study·DateOct 26, 2022

In pre-clinical trials, drug shows potential to combat exaggerated inflammation associated with COVID-19

A new study suggests that niclosamide, an anthelmintic drug, shows promise in combating exaggerated inflammation associated with severe COVID-19. The drug's anti-inflammatory effects are attributed to its inhibition of the inflammasome mechanism, a protein complex present in defense cells.

Current FDA oversight of vaping industry likely to have minimal impact

The FDA's warning letters issued in 2020 and 2021 revealed that the regulator is failing to target leading tobacco companies and products most popular among young people. Over 90% of warnings were sent to small online retailers, while flavoured refillable e-cigarette liquids accounted for over 90% of the products cited.

SourceBMJ Group·JournalTobacco Control·TypeData/statistical analysis·DateOct 13, 2022

STTR Award to LSU Health New Orleans spin-out company to develop new class of anticancer drugs for glioblastoma

WayPath Pharma has been awarded a $225,000 Phase I Small Business Technology Transfer (STTR) award to develop new metabolic drugs targeting tumor stem cells and crossing the blood-brain barrier. The funding aims to advance treatment options for glioblastoma, a highly aggressive brain cancer with limited treatment options.

NTU Singapore scientists’ discovery of the structure of a key part of our chromosomes could improve understanding of how humans age and develop cancer

Scientists from NTU Singapore have discovered that telomeres are stacked in columns like a spring, leaving DNA exposed to damage. This finding could improve understanding of how humans age and develop cancer, with potential treatments for diseases caused by dysfunctional telomeres.

Awakening «dormant» cells to fight cancer

A team from UNIGE and HUG identified a protein regulation mechanism that reduces melanoma cells' capacity to adapt and resist treatment. They found that targeting this mechanism with an enzyme inhibitor reduces therapeutic resistance in all melanoma cells.

SourceUniversité de Genève·JournalBiochemical and Biophysical Research Communications·DateSep 22, 2022

Study uncovers mechanism behind virus-induced heart inflammation, suggests potential therapeutic target

Researchers have identified two NLRP sensors, NLRP1 and CARD8, as key players in Coxsackievirus B3-induced heart inflammation. Targeting CARD8 may prevent CVB3 infections from progressing to heart failure. The study provides new insights into the inflammatory response triggered by this common viral cause of viral myocarditis.

SourceDuke-NUS Medical School·JournalJournal of Experimental Medicine·TypeExperimental study·DateSep 21, 2022

C-Path awarded FDA grant to establish public-private partnership to advance treatments for rare neurodegenerative diseases

The Critical Path Institute (C-Path) has established a public-private partnership with the FDA and NIH to advance treatments for rare neurodegenerative diseases. The partnership will leverage C-Path's expertise in data management, quantitative analytics, and regulatory science to accelerate medical product development.

Not just a backup – the dual specificity of UBA6

The research team at the University of Würzburg has reported the first structures of UBA6 in complex with either ATP or FAT10, shedding light on its dual recognition capability. The study also identified UBA6 variants that selectively abolish the activation of either ubiquitin or FAT10.

SourceUniversity of Würzburg·JournalNature Communications·TypeExperimental study·DateSep 9, 2022

Old drugs hint at new ways to beat chronic pain

A newly identified link between chronic pain and lung cancer in mice suggests that old drugs such as clonidine, capsaicin, and fluphenazine may offer new treatments for chronic pain. The study found that blocking the BH4 pathway reduced pain sensitivity and decreased tumor growth in mouse models of KRAS-driven lung cancer.

SourceIMBA- Institute of Molecular Biotechnology of the Austrian Academy of Sciences·JournalScience Translational Medicine·TypeExperimental study·DateAug 31, 2022